An FDA panel of outside experts is expected to review Pfizer Inc.’s (PFE) supplemental new drug applications for XELJANZ and XELJANZ XR for the treatment of adult patients with active psoriatic arthritis on August 3, 2017.XELJANZ is an immediate release tablet that releases medication into the bloodstream over the course of several hours, and is taken twice daily. XELJANZ XR is an extended release tablet that releases medication into the bloodstream over the course of a day, and is taken only once a day. XELJANZ and XELJANZ XR are already approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis. The drugs netted sales of $927 million in 2016, up 77% compared to 2015.PFE closed Friday's (July 28) trading at $33.15, up 0.45%.